Baxalta Inc  

(Public, NYSE:BXLT)    
Find more results for WAYNE J. GAVIN

Officers and directors

Ludwig N. Hantson Ph.D.
President, Chief Executive Officer, Director
Robert J. Hombach CPA
Chief Financial Officer, Chief Operating Officer, Executive Vice President
John J. Orloff M.D.
Executive Vice President, Head of Research & Development, Chief Scientific Officer
John Glasspool
Executive Vice President, Head - Corporate Strategy and Customer Operations
Brian Goff
Executive Vice President, President - Hematology
Anne-Marie Law
Executive Vice President, Head of Human Resources
Ronald K. Lloyd
Executive Vice President, President - Immunology
David D. Meek
Executive Vice President, President - Oncology
Dagmar Rosa-Bjorkeson
Executive Vice President, President - Biosimilars
Patrice Zagame M.D.
Executive Vice President, President - Intercontinental


1 Baxter Pkwy
DEERFIELD, IL 60015-4625
United States - Map
+1-224-9482000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Baxalta Incorporated is a biopharmaceutical company. The Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions. The Company also focuses on disease areas, including oncology, as well as technology platforms, including gene therapy and biosimilars. The Company has a portfolio of various therapies that address unmet medical needs across various disease areas, including hemophilia, immunology and oncology. The Company's products include ADVATE, RECOMBINATE, HEMOFIL M, Immunate, Immunine, PROTHROMPLEX TOTAL, RIXUBIS, FACTOR VII NF, BEBULIN, FEIBA, OBIZUR, GAMMAGARD LIQUID, GAMMAGARD S/D, Subcuvia, HYQVIA, FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP, CEPROTIN and ANTITHROMBIN III IMMUNO.

Related companies

* Delayed by up to 20 minutes -  Disclaimer